US CDC’s Adult RSV Vaccine Recommendations In Flux With Impending FDA Approvals

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

Moderna touts enriched Phase II/III population and severe RSV data as CDC advisory committee re-evaluates shared clinical decision-making and prepares for expected June votes on Moderna’s mRNA-1345 and expanded adult use of GSK’s Arexvy.

older woman coughing with cartoon of her lungs drawn over her image.
CDC will likely update its recommendations on adult RSV vaccines in June. • Source: Shutterstock

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices laid the groundwork recently for what could be a momentous 26-28 June meeting for adult respiratory syncytial virus (RSV) vaccine policy.

Key Takeaways

  • CDC Advisory Committee on Immunization Practices is evaluating the experience of the first RSV season with approved vaccines as it re-evaluates its shared clinical decision-making recommendation for GSK’s Arexvy and Pfizer’s Abrysvo in adults ages 60 and older.

The ACIP is revisiting the shared clinical decision-making status of its adult RSV recommendations while preparing for the impending approval...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By Vibha Sharma

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.